Replies to post #86463 on Biotech Values

[DewDiligence]

The hole in DCGN’s business model cited in the NYT article vis-à-vis the evolution of “bad” genes seems readily apparent in retrospect.

[DewDiligence]

New DeCode emerges from bankruptcy with guess who as head of research…

yep, Kari Stefansson:

http://finance.yahoo.com/news/Announcing-the-New-prnews-3474591365.html?x=0&.v=101

http://www.nytimes.com/2010/01/22/business/global/22gene.html

[DewDiligence]

Time warp—AMGN acquires DeCode Genetics for $415M in cash:

http://www.forbes.com/sites/matthewherper/2012/12/10/with-decode-deal-amgen-aims-to-discover-drugs-like-we-meant-to-1999/

“It was really working on targets like PCSK9 [for heart disease] or our sclerostin program [for osteoporosis] which are the two biggest assets in our pipeline that really drove home the immense value of having targets that have either been discovered or validated by the kind of human genetic analysis that Decode is a world expert in,” [Sean] Harper [AMGN’s head of R&D] says. “Having that information that those targets are relevant in human disease as opposed to not having it and relying on animal models is a huge thing for us given that we can only explore a small number of drug targets in any given time.”

DeCode went bankrupt in 2009 (#msg-43668895) and was purchased by Polaris Venture Partners and Arch Venture Partners for $14M. These private investors have thus made a 30-fold return on their investment, which is not bad in three years!

[DewDiligence]

WX acquires DeCode Genetics spin-off (NextCODE) for $65M:

http://www.xconomy.com/boston/2015/01/09/second-exit-for-decode-investors-as-spinout-nextcode-sold-to-wuxi/

AMGN acquired the reincarnation of DeCode for $415M in Dec 2012 (#msg-82321447).